Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$0.99 -2.6%	$0.97	$0.69 ▼ $3.94	$196.93M	0.67	4.91 million shs	4.00 million shs
GYRE Gyre Therapeutics	$7.42 +0.5%	$9.06	$6.11 ▼ $19.00	$695.68M	1.79	127,564 shs	1.05 million shs
NRIX Nurix Therapeutics	$11.64 -1.7%	$11.03	$8.18 ▼ $29.56	$887.39M	2.15	838,550 shs	2.06 million shs
OCS Oculis	$19.35 -0.7%	$18.76	$10.79 ▼ $23.08	$844.86M	0.35	45,391 shs	10,103 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	0.00%	-7.14%	+14.13%	-33.76%	-54.42%
GYRE Gyre Therapeutics	0.00%	-8.05%	-21.56%	-18.55%	-20.73%
NRIX Nurix Therapeutics	0.00%	+1.31%	+9.40%	-4.20%	-43.11%
OCS Oculis	0.00%	+0.36%	-0.77%	+0.89%	+63.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.1154 of 5 stars	3.4	3.0	3.9	2.2	1.7	0.6
GYRE Gyre Therapeutics	0.2855 of 5 stars	0.0	2.0	0.0	2.6	0.8	0.0
NRIX Nurix Therapeutics	1.1471 of 5 stars	3.4	0.0	0.0	2.0	0.8	0.0
OCS Oculis	2.1524 of 5 stars	3.5	3.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	604.51% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	159.25% Upside
OCS Oculis	3.00	Buy	$35.33	82.60% Upside

Current Analyst Ratings Breakdown

Latest ESPR, NRIX, GYRE, and OCS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/9/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/17/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $32.00
4/17/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/9/2025	NRIX Nurix Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $25.00
4/9/2025	NRIX Nurix Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $35.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.59	$0.02 per share	41.36	($1.97) per share	-0.50
GYRE Gyre Therapeutics	$105.76M	6.58	$0.20 per share	37.57	$1.05 per share	7.07
NRIX Nurix Therapeutics	$54.55M	16.27	N/A	N/A	$7.44 per share	1.56
OCS Oculis	$780K	1,083.10	N/A	N/A	$1.91 per share	10.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.02	371.19	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.64	N/A	N/A	N/A	-13,788.70%	-92.95%	-70.03%	8/19/2025 (Estimated)

Latest ESPR, NRIX, GYRE, and OCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million
5/8/2025	Q1 2025	OCS Oculis	-$0.51	-$0.77	-$0.26	-$0.77	$0.22 million	$0.32 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
GYRE Gyre Therapeutics	N/A	3.60	3.19
NRIX Nurix Therapeutics	N/A	6.26	6.26
OCS Oculis	N/A	4.79	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
GYRE Gyre Therapeutics	23.99%
NRIX Nurix Therapeutics	N/A
OCS Oculis	22.30%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
GYRE Gyre Therapeutics	10.00%
NRIX Nurix Therapeutics	7.40%
OCS Oculis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable

ESPR, NRIX, GYRE, and OCS Headlines

Recent News About These Companies

Oculis Holding AG (OCS) - Yahoo Finance

June 28 at 2:36 PM | sg.finance.yahoo.com

Oculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short Interest

June 17, 2025 | marketbeat.com

Leerink Partnrs Forecasts Oculis' Q2 Earnings (NASDAQ:OCS)

June 9, 2025 | marketbeat.com

Oculis Publishes Results of 2025 Annual General Meeting

June 5, 2025 | globenewswire.com

Oculis Publishes Results of 2025 Annual General Meeting

June 5, 2025 | globenewswire.com

Citadel Advisors LLC Buys Shares of 22,911 Oculis Holding AG (NASDAQ:OCS)

June 4, 2025 | marketbeat.com

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

June 3, 2025 | globenewswire.com

Oculis to Participate in Upcoming June Investor Conferences

June 3, 2025 | markets.businessinsider.com

Oculis Holding AG Announces Participation in Upcoming Investor Conferences in June 2025

June 3, 2025 | quiverquant.comQ

Oculis to Participate in Upcoming June Investor Conferences

June 3, 2025 | globenewswire.com

Oculis to Participate in Upcoming June Investor Conferences

June 3, 2025 | globenewswire.com

Oculis Holding AG: Oculis Reports Q1 Financial Results and Provides Company Update

May 11, 2025 | finanznachrichten.de

Oculis Publishes Invitation to the Annual General Meeting

May 9, 2025 | globenewswire.com

Oculis Publishes Invitation to the Annual General Meeting

May 9, 2025 | globenewswire.com

Oculis posts widening quarterly loss as R&D spend climbs

May 9, 2025 | thepharmaletter.comT

Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Oculis Reports Q1 Financial Results and Provides Company Update

May 8, 2025 | globenewswire.com

Oculis Reports Q1 2025 Financial Results and Provides Company Update

May 8, 2025 | globenewswire.com

Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline

May 7, 2025 | zacks.com

Oculis to Present at Upcoming May Investor Conferences

May 7, 2025 | globenewswire.com

Oculis to Present at Upcoming May Investor Conferences

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR, NRIX, GYRE, and OCS Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$0.99 -0.03 (-2.59%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+1.05%)

As of 06/27/2025 05:44 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Gyre Therapeutics NASDAQ:GYRE

$7.42 +0.04 (+0.54%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.42 0.00 (0.00%)

As of 06/27/2025 06:08 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Nurix Therapeutics NASDAQ:NRIX

$11.64 -0.20 (-1.69%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.64 0.00 (0.00%)

As of 06/27/2025 05:25 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Oculis NASDAQ:OCS

$19.35 -0.13 (-0.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$19.33 -0.02 (-0.10%)

As of 06/27/2025 04:04 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time